63 related articles for article (PubMed ID: 27720733)
1. Reproducibility of SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients.
Righi S; Pileri S; Agostinelli C; Bacci F; Spagnolo S; Sabattini E
Hum Pathol; 2017 Jan; 59():94-101. PubMed ID: 27720733
[TBL] [Abstract][Full Text] [Related]
2. Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma.
Chuang WY; Chang H; Shih LY; Lin TC; Yeh CJ; Ueng SH; Kuo MC; Kao HW; Liu H; Chang ST; Lee CL; Huang KP; Wang TH; Wan YL; Yu JS; Hsueh C; Chuang SS
Virchows Arch; 2024 May; ():. PubMed ID: 38733379
[TBL] [Abstract][Full Text] [Related]
3. Leukemic non-nodal cyclin D1- and SOX11-negative mantle cell lymphoma with CCND3::IGH rearrangement.
Tan L; Bansal G; Yeung CC; Yin J; Dave BJ; Konnick E; Wu D; Naresh KN
Ann Hematol; 2024 Feb; 103(2):667-669. PubMed ID: 37882866
[No Abstract] [Full Text] [Related]
4. SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma?
Li S; Tang G; Jain P; Lin P; Xu J; Miranda RN; Cheng J; Yin CC; You MJ; Wang ML; Medeiros LJ
Mod Pathol; 2024 Feb; 37(2):100405. PubMed ID: 38104893
[TBL] [Abstract][Full Text] [Related]
5. [Comprehensive Diagnosis of Mantle Cell Lymphoma].
Yang H; Guo R; Shi Y; Wang R; Qiao C; Wu YJ; Fan L; Xu W; Li JY; Qiu HR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1720-1725. PubMed ID: 38071051
[TBL] [Abstract][Full Text] [Related]
6. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Morsy MHA; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 Jan; 143(19):1953-1964. PubMed ID: 38774451
[TBL] [Abstract][Full Text] [Related]
7. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Abdelrazak Morsy MH; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 May; 143(19):1953-1964. PubMed ID: 38237141
[TBL] [Abstract][Full Text] [Related]
8. Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma.
Ramsower CA; Maguire A; Robetorye RS; Feldman AL; Syrbu SI; Rosenthal AC; Rimsza LM
J Hematop; 2020 Dec; 13(4):231-238. PubMed ID: 33193905
[TBL] [Abstract][Full Text] [Related]
9. Balsas P, Veloza L, Clot G, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202-2215.
Blood; 2023 Sep; 142(13):1173-1176. PubMed ID: 37768692
[No Abstract] [Full Text] [Related]
10. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia.
Cheng J; Ge T; Zhu X; Wang J; Zeng Y; Mu W; Cai H; Dai Z; Jin J; Yang Y; Hu G; Mao X; Zhou J; Zhu L; Huang L
Cancer Immunol Immunother; 2023 Jul; 72(7):2331-2346. PubMed ID: 36932256
[TBL] [Abstract][Full Text] [Related]
11. Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy.
Nagato T; Komatsuda H; Hayashi R; Takahara M; Kishibe K; Yasuda S; Yajima Y; Kosaka A; Ohkuri T; Oikawa K; Harabuchi S; Kono M; Yamaki H; Wakisaka R; Hirata-Nozaki Y; Ohara K; Kumai T; Katada A; Hayashi T; Harabuchi Y; Kobayashi H
Cancer Immunol Immunother; 2023 Jul; 72(7):2087-2098. PubMed ID: 36811663
[TBL] [Abstract][Full Text] [Related]
12. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
[TBL] [Abstract][Full Text] [Related]
13. Systematic Investigation of the Multifaceted Role of
Sun Q; Du J; Dong J; Pan S; Jin H; Han X; Zhang J
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551589
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors.
Gerdtsson AS; Matos Rodrigues J; Eskelund CW; Husby S; Grønbæk K; Räty R; Kolstad A; Geisler C; Porwit A; Jerkeman M; Ek S
Haematologica; 2023 Apr; 108(4):1092-1104. PubMed ID: 36519324
[TBL] [Abstract][Full Text] [Related]
15. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.
Balsas P; Veloza L; Clot G; Sureda-Gómez M; Rodríguez ML; Masaoutis C; Frigola G; Navarro A; Beà S; Nadeu F; Giné E; López-Guillermo A; Martínez A; Ribera-Cortada I; Engel P; Quintanilla-Martínez L; Klapper W; Campo E; Amador V
Blood; 2021 Dec; 138(22):2202-2215. PubMed ID: 34189576
[TBL] [Abstract][Full Text] [Related]
16. SOX11, a key oncogenic factor in mantle cell lymphoma.
Beekman R; Amador V; Campo E
Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333
[TBL] [Abstract][Full Text] [Related]
17. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V
Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307
[TBL] [Abstract][Full Text] [Related]
18. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.
Beà S; Amador V
Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437
[TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Jain P; Wang ML
Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-138 inhibits SOX12 expression and the proliferation, invasion and migration of ovarian cancer cells.
Qu M; Zhu Y; Jin M
Exp Ther Med; 2018 Sep; 16(3):1629-1638. PubMed ID: 30186381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
